ArticleClinical ophthalmology (Auckland, N.Z.)2026
Artificial Intelligence Driven Adjusted OCT-Based Classification System for Diabetic Macular Edema (AIDME).
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate an adjusted scoring-based classification system for Diabetic Macular Edema (DME) using quantitative and qualitative parameters. The system aims to improve clinical decision making and correlate disease severity with visual outcomes. Methods: A cohort of patients with DME was analyzed using optical coherence tomography (OCT) data. Key quantitative variables included retinal thickness (RT), intraretinal fluid (IRF), and subretinal fluid (SRF), which were scored according to severity thresholds (0-2 points per parameter). Qualitative biomarkers, including disorganization of the retinal inner layers (DRIL) and epiretinal membrane (ERM), were incorporated as severity modifiers (+2 for DRIL and +1 for ERM). The patients were classified based on the total score as follows: Mild (0-3 points), Moderate (4-6 points), and severe (>7 points). Visual acuity (logMAR) was analyzed to validate the system and to assess its correlation with disease severity. Statistical analyses included descriptive summaries and ANOVA for intergroup comparisons. Results: A total of 71 patients were classified into three groups: mild (48 patients, mean logMAR 0.45), moderate (18 patients, mean logMAR 0.56), and severe (5 patients, mean logMAR 0.92). The system showed significant differences in logMAR values (p = 0.014). ROC curve analysis showed an area under the curve (AUC) of 0.89. This adjusted scoring method aligned well with the clinical expectations, emphasizing the impact of fluid accumulation and structural biomarkers on vision impairment. Conclusion: The adjusted scoring-based classification system for DME demonstrated a robust correlation between the disease severity and visual acuity. Integrating quantitative measures and qualitative markers offers a practical and clinically relevant approach for stratifying DME severity. This method has the potential to enhance decision making in routine practice and research applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.